Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ 54.0 Cr.
- Current Price ₹ 58.5
- High / Low ₹ 89.0 / 46.1
- Stock P/E 52.4
- Book Value ₹ 37.7
- Dividend Yield 0.00 %
- ROCE 7.15 %
- ROE 3.01 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 37.5%
- Tax rate seems low
- Company has a low return on equity of 9.14% over last 3 years.
- Working capital days have increased from 73.4 days to 126 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
0 | 243 | 191 | 212 | 151 | |
0 | 235 | 178 | 205 | 143 | |
Operating Profit | -0 | 8 | 13 | 8 | 7 |
OPM % | 3% | 7% | 4% | 5% | |
0 | 0 | 0 | 0 | 0 | |
Interest | 0 | 3 | 2 | 3 | 5 |
Depreciation | 0 | 2 | 2 | 2 | 3 |
Profit before tax | -0 | 4 | 9 | 2 | 0 |
Tax % | 0% | 56% | 29% | 38% | -183% |
-0 | 2 | 7 | 1 | 1 | |
EPS in Rs | -0.24 | 1.93 | 7.20 | 1.36 | 1.12 |
Dividend Payout % | 0% | 0% | 14% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -15% |
TTM: | -29% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -17% |
TTM: | -18% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -16% |
1 Year: | 9% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 9% |
Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 0 | 9 | 9 | 9 | 9 |
Reserves | -0 | 17 | 24 | 24 | 26 |
0 | 12 | 27 | 31 | 44 | |
0 | 70 | 74 | 51 | 38 | |
Total Liabilities | 0 | 109 | 133 | 116 | 117 |
0 | 20 | 21 | 27 | 27 | |
CWIP | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 |
0 | 89 | 112 | 89 | 90 | |
Total Assets | 0 | 109 | 133 | 116 | 117 |
Cash Flows
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
0 | 27 | 8 | -10 | -11 | |
0 | -8 | -4 | -7 | 0 | |
0 | 19 | 12 | 0 | 11 | |
Net Cash Flow | 0 | 38 | 16 | -16 | -0 |
Ratios
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 64 | 69 | 60 | 77 | |
Inventory Days | 73 | 109 | 98 | 158 | |
Days Payable | 114 | 161 | 74 | 103 | |
Cash Conversion Cycle | 23 | 17 | 84 | 131 | |
Working Capital Days | 28 | 28 | 66 | 126 | |
ROCE % | 34% | 23% | 9% |
Documents
Announcements
- Closure of Trading Window 26 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Newspaper advertisement of the Audited Financial Results for the Fourth quarter and the Financial Year ended on March 31, 2024 as published in the following …
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Stock Exchanges on May 28, 2024 the Annual Secretarial Compliance Report issued by a Practicing Company Secretary for the financial year ended on March 31, …
-
Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)
29 May - Company in its meeting held today i.e. , on May 29, 2024 has : Approved the resignation of Mr. Satish Pandurang Samant (DIN : 10294920) …
-
Announcement under Regulation 30 (LODR)-Resignation of Director
29 May - Company in its meeting held today i.e. , on May 29, 2024 has : Taken note of resignation of Mr. Satish Pandurang Samant (DIN : …
Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.